Evidence map›Paper›PMID 38260234›Full record

ArticleAdvances in radiation oncology2024

Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy.

Ryan F Amidon, Katie Livingston, Christopher J Kleefisch, Michael Martens, Michael Straza, Lindsay Puckett, Christopher J Schultz, Wade M Mueller, Jennifer M Connelly, George Noid and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ryan F AmidonSchool of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Katie LivingstonRadiation Oncology Associates, Ltd, Mequon, Wisconsin.
Christopher J KleefischRadiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael MartensBiostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael StrazaRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Lindsay PuckettRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Christopher J SchultzRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Wade M MuellerNeurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Jennifer M ConnellyNeurology, Medical College of Wisconsin, Milwaukee, Wisconsin.
George NoidRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Kirk MorrisRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Joseph A BoviRadiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Medical College of Wisconsin · USRadiation Oncology Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The response of cystic brain metastases (BMets) to radiation therapy is poorly understood, with conflicting results regarding local control, overall survival, and treatment-related toxicity. This study aims to examine the role of Gamma Knife (GK) in managing cystic BMets. Methods and Materials: Volumetric analysis was conducted to measure tumor and edema volume at the time of GK and follow-up magnetic resonance imaging studies. Survival was described using the Kaplan-Meier method, and the cumulative incidence of progression was described using the Aalen-Johansen estimator. We evaluated the association of 4 variables with survival using Cox regression analysis. Results: Between 2016 and 2021, 54 patients with 83 cystic BMets were treated with GK at our institution. Lung cancer was the most common pathology (51.9%), followed by breast cancer (13.0%). The mean target volume was 2.7 cm Conclusions: Pre-GK WBRT may select for BMets with increased radioresistance. This study highlights the ability of GK to control cystic BMets with the cost of high posttreatment steroid use.

Identifiers

PMID38260234
PMCPMC10801666
OpenAlexW4382456891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.